Table 3.
Changes in anthropometric, biochemical, and MRI parameters after 6 mo of treatment with sitagliptin vs placebo
|
Placebo (n = 6) |
Sitagliptin (n = 6) |
Difference | |||
| Baseline | Post-treatment | Baseline | Post-treatment1 | (95%CI) | |
| Anthropometric and biochemical parameters | |||||
| Weight (kg) | 105.8 ± 23.5 | 104.7 ± 23.7 | 100.4 ± 28.7 | 101.1 ± 32.4 | 0.8 (-6.3, 8.0) |
| BMI (kg/m2) | 37.4 ± 4.7 | 36.8 ± 4.6 | 35.9 ± 6.6 | 35.8 ± 8.0 | 0.6 (-2.8, 4.0) |
| HbA1C (%) | 8.2 ± 0.9 | 8.0 ± 1.7 | 7.9 ± 1.0 | 6.7 ± 0.4a | -0.7 (-1.7, 0.4) |
| HOMA-IR | 3.5 ± 2.2 | 2.73 ± 1.631 | 3.4 ± 1.2 | 3.5 ± 2.9 | -0.36 (-3.3,2.6) |
| Triglycerides (mmol/L) | 2.33 ± 2.00 | 2.29 ± 1.40 | 2.80 ± 1.64 | 1.26 ± 0.43b | -1.10 (-2.88, 0.66) |
| HDL-C (mmol/L) | 1.10 ± 0.34 | 1.11 ± 0.29 | 1.12 ± 0.46 | 1.12 ± 0.40 | -0.05 (-0.32, 0.22) |
| LDL-C (mmol/L) | 1.61 ± 0.71 | 1.42 ± 0.34 | 1.42 ± 0.97 | 1.54 ± 0.51 | 0.30 (-0.17, 0.77) |
| Free fatty acids (μmol/L) | 645 ± 195 | 914 ± 411 | 559 ± 158 | 488 ± 270 | -143 (-788, 503) |
| Platelet aggregation (PRU) | 292 ± 37 | 266 ± 63 | 236 ± 28 | 251 ± 74 | -11 (-92, 70) |
| AST (IU/L) | 39 ± 19 | 42 ± 23 | 44 ± 22 | 35 ± 9 | -5 (-36, 26) |
| ALT (IU/L) | 46 ± 36 | 48 ± 28 | 72 ± 50 | 51 ± 15 | -5 (-51, 41) |
| Alk phos (IU/L) | 85 ± 34 | 97 ± 43 | 93 ± 41 | 76 ± 28 | -14 (-36, 7) |
| GGT (IU/L) | 100 ± 98 | 153 ± 176 | 164 ± 182 | 90 ± 76 | -62 (-164, 39) |
| Adiponectin (μg/mL) | 2.01 ± 1.30 | 2.09 ± 1.14 | 3.93 ± 2.65 | 4.70 ± 3.46b | 0.60 (-0.13, 1.32)c |
| Adipsin (μg/mL) | 0.62 ± 0.26 | 0.61 ± 0.26 | 0.66 ± 0.14 | 0.62 ± 0.07 | -0.07 (-0.26, 0.13) |
| Visfatin (ng/mL) | 3.21 ± 3.64 | 3.94 ± 3.59 | 1.82 ± 2.33 | 1.70 ± 1.08 | -0.58 (-3.26, 2.09) |
| Leptin (ng/mL) | 14.62 ± 12.52 | 17.64 ± 16.20 | 9.61 ± 3.29 | 8.87 ± 5.54 | -3.5 (-8.6, 1.6) |
| Resistin (ng/mL) | 3.66 ± 1.01 | 4.31 ± 1.66 | 7.19 ± 8.66 | 4.55 ± 1.73 | -4.05 (-11.33, 2.34) |
| TNF-α (pg/mL) | 3.69 ± 1.22 | 4.95 ± 4.79 | 2.85 ± 0.66 | 5.14 ± 3.20 | 0.95 (-4.70, 6.61) |
| IL-6 (pg/mL) | 5.89 ± 1.37 | 6.19 ± 2.37 | 7.15 ± 6.22 | 6.40 ± 3.41 | -1.44 (-7.76, 4.87) |
| MRI parameters | |||||
| Hepatic fat (%) | 21.9 ± 10.6 | 19.1 ± 9.6 | 19.0 ± 9.7 | 16.1 ± 12.9 | 2.0 (-7.3, 11.2) |
| SAAT (%) | 40.5 ± 7.1 | 39.8 ± 7.7 | 38.0 ± 22.0 | 34.1 ± 20.1 | 0.7 (-2.3, 3.7) |
| VAT (%) | 30.5 ± 3.4 | 30.3 ± 4.4 | 26.8 ± 11.6 | 27.6 ± 13.4 | 0 (-6.4, 6.4) |
1
One subject was excluded from the post-treatment, placebo group homeostasis model of assessment for insulin resistance (HOMA-IR) calculation due to blood glucose level above the acceptable steady-state glucose value for calculation of HOMA-IR.
a
P < 0.05 vs baseline;
b
P < 0.10 vs baseline;
c
P < 0.10 vs control.